Catia Carconi, Research Scholar at The Netherlands Cancer Institute, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in The Lancet:
“Proud to finally share our publication in The Lancet.
In the CASSANDRA trial, PAXG significantly improved event-free survival compared with mFOLFIRINOX in resectable and borderline-resectable pancreatic cancer, supporting preoperative PAXG as a new standard option and the standard comparator for future trials.
It has been a privilege to contribute to this work alongside patients and outstanding collaborating colleagues across Italy.
CASSANDRA was entirely funded by patient associations, a powerful example of what independent research and community commitment can achieve.
A special thank you to my mentor Michele Reni for teaching me the value of perseverance and scientific integrity.
To all the CASSANDRA, unheard voices whose ideas shape the future.”
Title: Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
Authors: Michele Reni, Marina Macchini, Giulia Orsi, Letizia Procaccio, Giuseppe Malleo, Catia Carconi, Ilario Giovanni Rapposelli, Katia Bencardino, Mario Scartozzi, Gianpaolo Balzano, Domenico Tamburrino, Barbara Merelli, Elisa Sperti, Giulio Belfiori, Nicole Liscia, Silvia Bozzarelli, Mariacristina Di Marco, Emiliano Tamburini, Michele Milella, Sara Lonardi, Giorgio Ercolani, Michele Mazzola, Diego Palumbo, Valter Torri, Massimo Falconi
Read the Full Article on The Lancet
More posts about Pancreatic cancer.